Neuregulin (Neuregulln, NRG) is a family of polypeptides encoded by four genes on the developing nervous system has a variety of important regulatory role. Brain tissue after ischemia and hypoxia due to the activation of a variety of mechanisms may cause brain edema and neuronal damage. Cerebral ischemia and hypoxia, microcirculation and cerebral ischemia after free radicals, arachidonic acid metabolites, excitatory amino acids and free fatty acids increased, resulting in severe vasogenic and cell-derived brain edema. Reduce cerebral blood flow, increased hypoxic injury and permeability of the vascular endothelial blood-brain barrier function damage, blood flow through the secondary brain edema. Brain edema and further aggravate ischemia and hypoxia of brain tissue, forming a vicious cycle. In the rat permanent MCAO model of ischemic penumbra zone cells can be observed NRG EthB its receptor tyrosine kinase receptor to induce the expression of positive. Xu Zhen peak experiments show that NRG anti-inflammatory substances in the body outside the central nervous system can inhibit brain ischemia-reperfusion injury-induced neuronal apoptosis, glial response and inflammation, induced expression of the neurotrophic factor have neuroprotective effects.
Artery occlusion and reperfusion (MCAO / R) model has been widely used in acute focal cerebral infarction studied in rat and rabbit brain. In this study, attempts to model NRG through carotid artery in mice with focal cerebral ischemia and reperfusion, by observing the neurobehavioral score, brain water content, changes in the scope of the ischemic penumbra, as well as immunofluorescence staining of nerve cells apoptosis, immunohistochemistry chemical detection of nerve cells AQP 4 expression, study neuroprotective NRG in ischemic brain injury and its mechanism of action, and to further explore the potential value of its clinical application. In particular, its anti-inflammatory, anti-apoptotic role of cerebral edema and reperfusion injury, it is possible to extend the time window of thrombolytic therapy, and increase safety and improve the prognosis of the treatment.